[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"myocardial-infarct\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:myocardial-infarct":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,78],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100587388","phase-2-focused-orticumab-research-for-treating-inflammation-in-coronary-arteries-100587388",false,"NCT06927739","Focused Orticumab Research for Treating Inflammation in Coronary Arteries","A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Orticumab in Participants With Prior Myocardial Infarction Who Have Elevated Coronary Inflammation Based on FAI Score Assessed by CCTA","FORTIFY","Inclusion Criteria:\n\n1. Participant must provide informed consent before any study specific activities are performed, must be able and willing to meet all requirements for randomization and must adhere to the schedules of activities.\n2. Participant must be \\>180 days after presumed type-1 myocardial infarction (i.e., due to plaque rupture or erosion, either STEMI or NSTEMI) without subsequent unstable or severe angina (Canadian Cardiovascular Society Class 3 or 4) at the time of enrollment. Participants who have undergone PCI are allowed.\n3. Participant must be on a stable cardiovascular treatment regimen consistent with local treatment guidelines for post-AMI patients (such as maximally tolerated statin and\u002For PCSK9 inhibitor medication for LDL reduction, antiplatelet medication, and hypertension treatment).\n4. Participant must have an evaluable, pre-randomization CCTA with one of the following:\n\n   1. A quantifiable Fat Attenuation Index (FAI) Score greater than or equal to the 50th centile (per reference standard) for their age group in at least two coronary arteries or\n   2. A quantifiable Fat Attenuation Index (FAI) Score greater than or equal to the 75th centile (per reference standard) for their age group in at least one coronary artery\n5. Participant must have body mass index (BMI) ≤ 40 kg\u002Fm2.\n6. Adult male and female participants ≥18 years of age at the Screening Visit:\n\nFor female participants, the participant must not be pregnant or lactating and must be one of the following:\n\n1. Postmenopausal, defined as amenorrhea for ≥ 12 months following cessation of all exogenous hormonal treatments; follicle stimulating hormone levels may be obtained at the investigator's discretion to confirm the participant is postmenopausal.\n2. Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy. Tubal ligation is not considered as irreversible surgical sterilization.\n3. Females of childbearing potential must have a negative serum or urine pregnancy test prior to the start of study drug. In the case of positive urine pregnancy testing, a negative serum sample for pregnancy testing, to confirm that the participant is not pregnant, must be obtained prior to start of study. They must also agree to use an adequate method of contraception from Baseline through the End of the study or for 30 days after the last dose of study drug (whichever is longer), which include the following: sexual abstinence (if preferred and usual lifestyle of the participant), condom with spermicidal gel, diaphragm with spermicidal gel, coil (intrauterine device), surgical sterilization, vasectomy, oral contraceptive pill, depo progesterone injections, progesterone implant (i.e., Implanon®), NuvaRing®, Ortho Evra®.\n\nFor male participants - Nonsterile male participants with sexual partners of childbearing potential must agree to use an adequate method of contraception, including sexual abstinence (if preferred and usual lifestyle of the participant), from Baseline through the End of the study.\n\nExclusion Criteria:\n\n1. History of any clinically important disease or disorder which, in the opinion of the investigator, may either put the participant at risk because of participation in the study, or influence the results or the participant's ability to participate in the study.\n2. Percutaneous coronary intervention or invasive diagnostic coronary angiogram planned after screening. Eligible participants who have an invasive diagnostic coronary angiogram performed in the absence of undergoing a new PCI may continue screening after the diagnostic angiogram has been performed or may be rescreened.\n3. History of or planned coronary artery bypass grafting.\n4. Documented episode of post-MI pericarditis in the 3 months before enrollment.\n5. Presence of unstable or uncontrolled angina. Canadian CV society (CCS) angina class \\> 2.\n6. Ongoing New York Heart Association Class IV HF.\n7. Poorly controlled type 1 or type 2 diabetes mellitus (hemoglobin A1c \\>8.0%).\n8. Increased risk of bleeding:\n\n   1. With history or presence of any bleeding disorder.\n   2. Signs of ongoing bleeding at screening (e.g., identified macroscopic bleeding, low hemoglobin presumed to be caused by bleeding) or high risk for major bleeding in accordance with the Investigator's assessment (participants taking clinically indicated antiplatelet and antithrombotic agents are acceptable).\n   3. Known severe liver disease (e.g., \\>5´ upper limit of normal elevations in ALT and\u002For AST and other evidence of grade 3 or higher criteria applies such as from the CTCAE 5.0 guidelines).\n9. History or presence of any of the following:\n\n   1. Ongoing infection or febrile illness.\n   2. Ongoing persistent or permanent atrial fibrillation or flutter.\n   3. Cancer within 5 years before randomization, with the exception of non-melanoma skin cancer.\n   4. Alcohol or substance abuse within 6 months before randomization, as judged by the investigator.\n   5. Known history of hypersensitivity reactions to other biologics, to human IgG preparations, or to any component of orticumab, or ongoing severe allergy as judged by the investigator.\n   6. Active positive results on screening for serum hepatitis C core antibody.\n   7. Clinically documented hepatitis B or HIV.\n10. Any clinically important abnormalities in clinical chemistry, hematology, coagulation parameters, as judged by the investigator.\n11. Blood pressure values at screening (taken as the average of triplicate measurements):\n\n    1. Systolic blood pressure \\\u003C 90 mmHg or \\> 180 mmHg.\n    2. Diastolic blood pressure \\> 100 mmHg.\n    3. One triplicate retest (repeat of all 3) will be allowed during the same visit, at which point if the retest result is no longer exclusionary, the participant may be randomized\n    4. Participants who are excluded based on elevated blood pressure may be rescreened following adequate treatment.\n12. Participants with any of the following contraindications to CCTA.\n\n    1. eGFR \\\u003C 40 mL\u002Fmin\u002F1.73 m2 by the Chronic Kidney Disease Epidemiology Collaboration equation, or end stage renal disease treated with kidney transplant or renal replacement therapy.\n    2. Allergy to iodinated contrast.\n    3. History of contrast-induced nephropathy.\n    4. Contraindication to nitroglycerin.\n    5. Rapid heart rate that is uncontrolled by medical therapy.\n    6. Inability to hold breath for at least 6 seconds.\n13. Use of any of the following in the 180 days before randomization: IL-17 inhibitor, TNF inhibitor, IL-6 inhibitor, IL-1β inhibitor, methotrexate, cyclosporine, apremilast, colchicine, systemic steroids (topical steroid use is allowed).\n14. COVID-19 vaccine within 90 days of screening CCTA.\n15. Participants with a confirmed positive COVID-19 test within 90 days of screening CCTA.\n16. Receipt of any investigational device or therapy within 6 months or 5 half-lives before screening (whichever is longer).\n17. Planned participation in an additional investigational study of an intervention or biologic before the end of the follow-up period. Participation in observational studies or studies without investigational drugs or devices is allowed.\n18. Participants who have previously been exposed to orticumab.\n19. Participants who are legally institutionalized.\n20. An employee or close relative of an employee of the sponsor, the CRO, or the study site, regardless of the employee or close relative's role.","ALL","18 Years",{"count":20,"type":21},240,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The goal of this clinical trial is to determine the clinical effect of orticumab treatment on inflammation in study participants with prior myocardial infarction who have elevated coronary inflammation based on CCTA. The main question it aims to answer is:\n\nClinical effects of orticumab treatment on inflammation of the coronary artery parameters measured with CCTA\n\nResearchers will compare the effects with placebo group after 6 months of treatment\n\nParticipants will Keep the planned study visit appointments Provide complete information about medical and medical history Speak to the study doctor before changing any of non-study treatments, including starting new medications, receiving any vaccinations, or setting out to join any other clinical studies",[27,28,29,30,31,32],"Acute Coronary Syndromes","Coronary Arterial Disease (CAD)","Inflammation","Heart Disease","Myocardial Infarct","Atherosclerotic Coronary Vascular Disease","RECRUITING","2026-01-24",{"date":36,"type":37},"2026-01-27","ACTUAL",{"date":39,"type":37},"2025-08-11",{"date":41,"type":21},"2027-06-01",{"name":43,"class":44},"Abcentra","INDUSTRY",41,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":77},"100559319","phase-4-stunning-in-acute-myocardial-infarction---bas-100559319","NCT06562582","STunning in Acute Myocardial Infarction - BAS","STunning in Acute Myocardial Infarction - Beta Blockers, Angiotensin Converting Enzyme Inhibitors and Sodium\u002FGlucose Cotransporter 2 Inhibitors Trial A Low Intervention Clinical Tria","STAMI-BAS","Inclusion Criteria:\n\n1. Patients with STEMI who undergo primary PCI within 6 hours of symptom onset (Excluding prodromal symptoms)\n2. Informed consent\n\nExclusion Criteria:\n\n1. Killip class ≥ 3\n2. Chronic kidney disease with GFR \\\u003C 25 ml\u002Fmin\u002F1.73 m2\n3. Pre-existing non-reversible cardiac dysfunction or heart failure\n4. Current treatment with any beta blocker, RAAS inhibitor or SGLT2 inhibitor\n5. Absolute or relative contraindication to any one of the study drugs that confers a risk of patient safety if the patient participates in the trial and adheres to the protocol-specified recommendations, per the assessment of the treating physician\n6. Life expectancy less than one year\n7. Pregnancy or women of childbearing potential who is not sterilized or is not using a medically accepted form of contraception",{"count":55,"type":21},120,[57],"PHASE4","The objective of this trial is to examine the effect of immediate versus late administration of beta blockers, angiotensin converting enzyme inhibitors (ACEI), and sodium\u002Fglucose cotransporter 2 (SGLT2) inhibitors on echocardiographic parameters and biomarkers in subjects with ST-elevation myocardial infarction (STEMI)",[31],[61,62,63,64,65,66],"ST infarction","PCI","Bisoprolol","Ramipril","Dapagliflozin","Global longitudinal strain (GLS, %)","2025-06-24",{"date":69,"type":37},"2025-06-27",{"date":71,"type":37},"2025-01-06",{"date":73,"type":21},"2027-12-31",{"name":75,"class":76},"Vastra Gotaland Region","OTHER_GOV",1,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":88,"briefSummary":90,"conditions":91,"keywords":93,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":77},"100567031","heart-attack-blood-oxygen-therapy-trial-100567031","NCT06662890","Heart Attack Blood Oxygen Therapy Trial","Supersaturated Oxygen Therapy Using Radial Artery Access to Prevent Left Ventricular Remodeling After Anterior ST-segment Elevation Myocardial Infarction: a Randomized, Controlled Trial","SSO2 Radial MI","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Ischemic time ≤6 hours from symptom onset\n3. Acute anterior ST-segment elevation myocardial infarction\n4. Infarct-related left anterior descending coronary artery TIMI flow grade 2-3 at the end of PCI\n5. Radial artery access\n6. Partial pressure of oxygen (PaO2) \\>80 mmHg (10.7 kPa)\n\nExclusion Criteria:\n\n1. Proximal coronary artery stenosis that restricts blood flow with the SSO2 catheter in place\n2. Post-PCI non-stented dissection or perforation.\n3. Moderate - severe heart valve stenosis, insufficiency, pericardial disease, or non-ischaemic cardiomyopathy\n4. Known pregnancy.\n5. Cardiogenic shock\n6. Contra-indication to anticoagulation\n7. Acute mechanical complication e.g., ventricular septal rupture, pseudoaneurysm, mitral regurgitation\n8. Hemoglobin \\\u003C10 g\u002FdL\n9. Major bleeding or major surgery within the past two months\n10. Contra-indication to cardiovascular magnetic resonance (CMR) imaging e.g., severe claustrophobia, metallic foreign body.\n11. Lack of witness verbal consent.",{"count":87,"type":21},56,[89],"NA","'Heart attack', known as acute ST-segment elevation myocardial infarction, is a leading cause of heart failure and death. A lack of blood and oxygen damages the heart muscle potentially causing heart failure and premature death.\n\nDuring the past 25 years, despite intensive research efforts, few, if any new medicines have been shown to prevent heart failure after a heart attack. New treatment approaches are needed.\n\nThe standard treatment for a heart attack is for a doctor to reopen the blocked blood vessel. The treatment is called primary percutaneous coronary intervention, or 'primary PCI'. The doctor places a thin plastic tube in a blood vessel in the wrist. The doctor then passes a longer thin tube via the wrist into the blocked heart artery. A small balloon is then used to open the blockage and a thin metal tube (stent) is placed inside the blood vessel to keep it open. The patient then returns to the ward.\n\nSupersaturated oxygen therapy is designed to increase the blood oxygen level after the stent has been placed. The treatment lasts for one hour. The treatment is approved (CE-mark, FDA-approved) for patients presenting to doctors within 6 hours of symptoms onset. Supersaturated oxygen therapy is supported by results from two prior studies (AMIHOT, AMIHOT-II). Previously, the approach involved passing the plastic tubes via the femoral artery in the groin, limiting adoption. Since using the wrist is now standard care approach for heart attack treatment, our idea is to give supersaturated oxygen therapy via the wrist rather than the groin.\n\nIn this research study, we aim to assess the feasibility, safety and potential benefits of increasing blood oxygen content in patients who have been treated for a heart attack. The novel aspects of the study including giving the therapy via the wrist, the dummy procedure (sham\u002Fplacebo), the randomized treatment assignment (coin-flip, play of chance), and the masking (blinding) of the patient participating in the study and the attending clinical staff, investigators and outcome assessors.\n\nPatients who have been successfully treated for a heart attack will be invited to give informed consent at the end of the procedure. Fifty-six patients who have experienced a heart attack affecting the main area of the heart (anterior wall) will receive supersaturated therapy, or a dummy procedure, for one hour. The dummy procedure involves local anesthetic in the wrist and a pressure band as would normally be done.\n\nThe study also involves measuring small vessel function before and after the supersaturated oxygen \u002F dummy procedure, a heart MRI scan at 2-5 days and again 3 months later, health questionnaires and blood samples to assess heart injury and to be stored for future research.\n\nThe study will provide information on safety, feasibility and preliminary insights into potential benefits to patients. The study will clarify whether a much larger study is warranted.",[31,92],"Remodeling, Left Ventricle",[94,95,96,97,98,99,100,101],"myocardial infarction","primary percutaneous coronary intervention","heart failure","adverse ventricular remodelling","biomarkers","coronary microvascular function","PREMS","PROMS","2025-02-21",{"date":104,"type":37},"2025-02-24",{"date":106,"type":37},"2024-10-25",{"date":108,"type":21},"2038-11-01",{"name":110,"class":111},"NHS National Waiting Times Centre Board","OTHER"]